Navigation Links
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

Cell Genesys, Inc. (Nasdaq: CEGE) today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with operable pancreatic cancer who received GVAX after surgical resection of their tumor and adjuvant radiation and chemotherapy. The median overall survival for these patients was previously reported to be 26.8 months, a result which compares favorably to the 17 to 22 months median survival results published from multiple studies in patients undergoing pancreatic cancer surgery and adjuvant therapy. Of note, 53 of the 60 patients were considered high risk, based on the unfavorable finding that their cancer had spread to regional lymph nodes. The new data reported today included a median disease-free survival of approximately 16 months which compares favorably to the 13 months disease-free survival recently reported for gemcitabine adjuvant therapy. Moreover, a comparison of the median overall survival of 60 patients from this trial with patients at Johns Hopkins with operable pancreatic cancer who underwent surgery and adjuvant therapy without receiving GVAX indicated that the median overall survival of the latter group was approximately 21 months or nearly six months shorter than the patients in the Phase 2 trial. The analysis of survival data further showed that the potential additive benefit of GVAX following surgery and adjuvant therapy was present during the first three years of the study although GVAX dosing did not continue beyond 18 months, suggesting that ongoing booster administrations of GVAX should be evaluated. Immunologic findings showed that there was an association between disease-free survival and treatment-associated antitumor immunity as measured by the induction of T cell responses to the pancreatic cancer-associated antigen, mesothelin (p=.01). The new findings were presented over the weekend by Daniel Lahe
'"/>




Page: 1 2 3 4

Related medicine news :

1. Russia Reports First SARS Case
2. Uganda Reports Failure To Contain Sleeping Sickness
3. Reports of Hantavirus infection in India raise concerns
4. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
5. China Reports Yet Another Bird Flu Case
6. Cyprus Reports H5N1 Strain In Birds
7. Reports Of New Bird Flu Outbreak In China Raise Concerns
8. Reports Of Denmark’s First Case Of Human Bird Flu Fals
9. Bird Flu Spreads To Sudan & China Reports Of Another Case
10. French Face Transplant Patient Reports Feeling of Sensation in New Face
11. Budhia Is Fine, Government-constituted Medical Board Reports False
Post Your Comments:
(Date:8/20/2014)... (PRWEB) August 20, 2014 Doctors at the ... to wipe out mesothelioma in laboratory mice by injecting them ... just posted details of the study on its website. ... Scientists with Hong Kong University’s AIDS Institute of Microbiology created ... 1” or PD-1. By altering DNA, the vaccine is designed ...
(Date:8/20/2014)... City, New Jersey (PRWEB) August 20, 2014 ... in meeting the needs of an estimated tens of ... introduction of the new Bill A3525—a bill that would ... patients to grow their own cannabis—earlier this summer by ... horticultural training for medicinal quality marijuana is growing. , ...
(Date:8/20/2014)... August is Children’s Eye Health and Safety ... eye health and safety for their children and have ... that must be checked for, according to Sharon Kleyne, ... radio show, is pediatric dry eye. With computer use ... is becoming a very real concern to ophthalmologists. , ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Hope For ... Give Hope® Celebration to be hosted in Washington, DC ... Navy Club. This signature event honors the courage of ... of the fallen. Proceeds from the Got Heart, Give ... national nonprofit dedicated to restoring a sense of self, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Building ... healthcare, Jvion successfully predicted stage iii and iv ... in some situations, approached 90%. A company spokesperson ... achieved in commercial or academic settings. The resulting ... all types of hospital-acquired conditions to help providers ...
Breaking Medicine News(10 mins):Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2
... The findings might boost understanding of the disease generally, ... The adult children of people with the rarer, inherited ... new study to better understand the biology of the ... biological parent diagnosed with a known genetic mutation causing ...
... 28 /PRNewswire-Asia/ -- CCID Consulting, China,s leading,research, consulting and ... listed in Hong Kong (Hong Kong Stock Exchange:,HK08235), recently ... , In 2007, ... an increase,in health awareness, which in turn drove the ...
... MD, noted medical researcher and women,s health practitioner, has spoken out ... well as other oral bisphosphonates such as Boniva, Actonel, and Fosamax. ... ... Susan Lark, MD , noted medical researcher and women,s health ...
... Africa, Nov. 27 20 top international,and local companies ... Awards Banquet held tonight at the Michelangelo Hotel in ... and innovation,across a variety of sectors. , ... , The awards ...
... after its use was banned, statistics show that nearly 4,000 people in the ... , ... Manchester,UK (PRWEB) November 27, 2008 -- On 24th November 1999, the Government,s ... statistics show that nearly 4,000 people in the UK die each year from ...
... care nurses are considering quitting in the next year ... Melbourne study. , The study, conducted by the Centre ... and the Australian Nursing Federation finds Victoria,s registered nurses ... not committed to their workplace. , It cites excessive ...
Cached Medicine News:Health News:Study Recruiting From Alzheimer's-Prone Families 2Health News:CCID Consulting Discusses China's Medical Equipment Market 2Health News:CCID Consulting Discusses China's Medical Equipment Market 3Health News:CCID Consulting Discusses China's Medical Equipment Market 4Health News:CCID Consulting Discusses China's Medical Equipment Market 5Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 2Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 3Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 4Health News:Frost & Sullivan Recognises Best-in-Class Innovators 2Health News:Frost & Sullivan Recognises Best-in-Class Innovators 3Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 2Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 3Health News:Aged care workers to leave industry en masse due to stress, warns University of Melbourne study 2
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
(Date:8/19/2014)... Md. , Aug. 19, 2014  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... offering announced last Thursday, August 14, 2014, has closed.  ... are convertible at $7.30 per share of common stock.  ... months, to purchase up to an additional 30% of ...
(Date:8/19/2014)... YORK , Aug. 19, 2014  As ... around the country, Bernstein Liebhard LLP notes that ... can choose between a number of options that ... dangerous surgical instrument. According to a report published ... th , these options include a mini-laparotomy and ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3
... 24 Children,s Mental Focus,Foundation (CMFF), a nonprofit ... that may be linked to children with autism ... currently working with,doctors that have patients afflicted with ... adults cope with behavioral problems,associated with mental disorders ...
... Marketers, who have the,primary responsibility for communicating the ... as top challenges for pharmaceutical,companies when communicating trial ... worry about competitors stealing your,thunder, but also worry ... According to a Best Practices, LLC benchmarking study, ...
Cached Medicine Technology:Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 2Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 3Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies 2
... versatile new test providing the broadest range ... The Multi-Target Stereo test can be used ... stereopsis, visual attention, form and depth perception, ... includes a pair of high quality reversible ...
... stereo tests provide accurate measurement of ... choice of polarized glasses. The original ... slipped into a thin plastic frame ... includes Richmonds new P/N 4465 Polycarbonate ...
Comes with seven test plates. Red and green glasses filters are mounted in two frames, one for adults and one for children. Suitable for testing very small children as well as adults....
Lumicon 48 mm red filter....
Medicine Products: